19-Dec-2025
No headlines found.
Globe Newswire (Mon, 8-Dec 8:00 AM ET)
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Tue, 25-Nov 8:00 AM ET)
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Globe Newswire (Thu, 13-Nov 8:30 AM ET)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 4-Nov 4:01 PM ET)
Globe Newswire (Sun, 26-Oct 11:30 AM ET)
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Globe Newswire (Tue, 14-Oct 8:00 AM ET)
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics trades on the NASDAQ stock market under the symbol FATE.
As of December 19, 2025, FATE stock price was flat at $1.05 with 2,691,925 million shares trading.
FATE has a beta of 2.13, meaning it tends to be more sensitive to market movements. FATE has a correlation of 0.12 to the broad based SPY ETF.
FATE has a market cap of $121.10 million. This is considered a Micro Cap stock.
Last quarter Fate Therapeutics reported $2 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $392,160 and exceeded earnings estimates by $.01.
In the last 3 years, FATE traded as high as $13.00 and as low as $.66.
The top ETF exchange traded funds that FATE belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
FATE has underperformed the market in the last year with a price return of -36.7% while the SPY ETF gained +18.1%. However, in the short term, FATE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.1% vs +2.8% return in SPY. But in the last 2 weeks, FATE shares have been beat by the market, returning -2.8% compared to an SPY return of -0.5%.
FATE support price is $1.00 and resistance is $1.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FATE shares will trade within this expected range on the day.
